[Skip to Content]
[Skip to Content Landing]
July 17, 1981

Posttransfusion Hepatitis in Acute Myelogenous Leukemia

Author Affiliations

University of Tennessee Memphis

JAMA. 1981;246(3):215-216. doi:10.1001/jama.1981.03320030013014

To the Editor.—  The report of Foon et al (1980;244:1806) suggesting that remission duration and survival in patients with acute myelogenous leukemia are favorably influenced by the development of posttransfusion hepatitis suffers from oversimplification and conveys an attitude toward hepatitis in leukemic patients that is potentially misleading.The definition of hepatitis used by the study is the finding of an elevation of SGOT to greater than 50 IU/L on two consecutive occasions. This is inadequate for the definition of post-transfusion hepatitis. No serological or morphological data are present to support their diagnoses. Although the hepatitis is called "posttransfusion," no information concerning components transfused, source of components used, number of transfusions, and relation of time of transfusion and time of onset of SGOT elevation is provided. The patients were receiving potentially hepatotoxic chemotherapy,1 yet no mention of actual dosage received by patients in each group is supplied. The data presented